Dakota Wealth Management Sells 9,924 Shares of Novo Nordisk A/S (NYSE:NVO)

Dakota Wealth Management reduced its position in shares of Novo Nordisk A/S (NYSE:NVO) by 29.3% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 23,984 shares of the company’s stock after selling 9,924 shares during the quarter. Dakota Wealth Management’s holdings in Novo Nordisk A/S were worth $2,063,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in NVO. Strategic Investment Solutions Inc. IL bought a new stake in Novo Nordisk A/S during the 2nd quarter valued at $25,000. Daiwa Securities Group Inc. bought a new position in Novo Nordisk A/S in the 3rd quarter worth $28,000. Capital Performance Advisors LLP bought a new position in Novo Nordisk A/S in the 3rd quarter worth $42,000. Carolina Wealth Advisors LLC bought a new position in Novo Nordisk A/S in the 3rd quarter worth $48,000. Finally, M&R Capital Management Inc. raised its holdings in Novo Nordisk A/S by 260.5% in the 3rd quarter. M&R Capital Management Inc. now owns 411 shares of the company’s stock worth $49,000 after purchasing an additional 297 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have commented on NVO shares. UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. BMO Capital Markets decreased their price objective on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a report on Monday, December 23rd. Cantor Fitzgerald restated an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. Finally, StockNews.com lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $145.25.

Novo Nordisk A/S Stock Performance

Shares of NVO stock opened at $81.36 on Friday. Novo Nordisk A/S has a one year low of $78.17 and a one year high of $148.15. The company’s 50-day moving average is $96.10 and its 200 day moving average is $115.79. The company has a market capitalization of $365.09 billion, a price-to-earnings ratio of 26.33, a price-to-earnings-growth ratio of 0.89 and a beta of 0.45. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.